These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 39107835)

  • 21. Retromer dysfunction at the nexus of tauopathies.
    Carosi JM; Denton D; Kumar S; Sargeant TJ
    Cell Death Differ; 2021 Mar; 28(3):884-899. PubMed ID: 33473181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of tau self-aggregation and neurotoxicity.
    Farías G; Cornejo A; Jiménez J; Guzmán L; Maccioni RB
    Curr Alzheimer Res; 2011 Sep; 8(6):608-14. PubMed ID: 21605046
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Understanding of Neurodegenerative Diseases Associated With the Protein Tau.
    Josephs KA
    Mayo Clin Proc; 2017 Aug; 92(8):1291-1303. PubMed ID: 28778262
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease.
    Stancu IC; Ferraiolo M; Terwel D; Dewachter I
    Adv Exp Med Biol; 2019; 1184():145-166. PubMed ID: 32096036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complicated Role of Post-translational Modification and Protease-Cleaved Fragments of Tau in Alzheimer's Disease and Other Tauopathies.
    Yang J; Shen N; Shen J; Yang Y; Li HL
    Mol Neurobiol; 2024 Jul; 61(7):4712-4731. PubMed ID: 38114762
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RNA and protein-dependent mechanisms in tauopathies: consequences for therapeutic strategies.
    Gallo JM; Noble W; Martin TR
    Cell Mol Life Sci; 2007 Jul; 64(13):1701-14. PubMed ID: 17453144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tau Proteins and Tauopathies in Alzheimer's Disease.
    Chong FP; Ng KY; Koh RY; Chye SM
    Cell Mol Neurobiol; 2018 Jul; 38(5):965-980. PubMed ID: 29299792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human cyclophilin 40 unravels neurotoxic amyloids.
    Baker JD; Shelton LB; Zheng D; Favretto F; Nordhues BA; Darling A; Sullivan LE; Sun Z; Solanki PK; Martin MD; Suntharalingam A; Sabbagh JJ; Becker S; Mandelkow E; Uversky VN; Zweckstetter M; Dickey CA; Koren J; Blair LJ
    PLoS Biol; 2017 Jun; 15(6):e2001336. PubMed ID: 28654636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assembly of recombinant tau into filaments identical to those of Alzheimer's disease and chronic traumatic encephalopathy.
    Lövestam S; Koh FA; van Knippenberg B; Kotecha A; Murzin AG; Goedert M; Scheres SHW
    Elife; 2022 Mar; 11():. PubMed ID: 35244536
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alzheimer's disease: phenotypic approaches using disease models and the targeting of tau protein.
    Lauretti E; Praticò D
    Expert Opin Ther Targets; 2020 Apr; 24(4):319-330. PubMed ID: 32116063
    [No Abstract]   [Full Text] [Related]  

  • 31. Posttranslational modifications of tau--role in human tauopathies and modeling in transgenic animals.
    Chen F; David D; Ferrari A; Götz J
    Curr Drug Targets; 2004 Aug; 5(6):503-15. PubMed ID: 15270197
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intracellular and extracellular roles for tau in neurodegenerative disease.
    Hanger DP; Lau DH; Phillips EC; Bondulich MK; Guo T; Woodward BW; Pooler AM; Noble W
    J Alzheimers Dis; 2014; 40 Suppl 1():S37-45. PubMed ID: 24595196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Functional Role of microRNAs in the Pathogenesis of Tauopathy.
    Praticò D
    Cells; 2020 Oct; 9(10):. PubMed ID: 33050194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stabilization of Monomeric Tau Protein by All D-Enantiomeric Peptide Ligands as Therapeutic Strategy for Alzheimer's Disease and Other Tauopathies.
    Altendorf T; Gering I; Santiago-Schübel B; Aghabashlou Saisan S; Tamgüney G; Tusche M; Honold D; Schemmert S; Hoyer W; Mohrlüder J; Willbold D
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease.
    Zhang ZY; Harischandra DS; Wang R; Ghaisas S; Zhao JY; McMonagle TP; Zhu G; Lacuarta KD; Song J; Trojanowski JQ; Xu H; Lee VM; Yang X
    Science; 2023 Jul; 381(6656):eadd6696. PubMed ID: 37499037
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The proceeding of drug development based on the propagation of tau protein].
    Suzuki G; Hasegawa M
    Nihon Rinsho; 2016 Mar; 74(3):432-7. PubMed ID: 27025082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration.
    Galán-Ganga M; Rodríguez-Cueto C; Merchán-Rubira J; Hernández F; Ávila J; Posada-Ayala M; Lanciego JL; Luengo E; Lopez MG; Rábano A; Fernández-Ruiz J; Lastres-Becker I
    Acta Neuropathol Commun; 2021 May; 9(1):90. PubMed ID: 34001284
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four-repeat tauopathies.
    Rösler TW; Tayaranian Marvian A; Brendel M; Nykänen NP; Höllerhage M; Schwarz SC; Hopfner F; Koeglsperger T; Respondek G; Schweyer K; Levin J; Villemagne VL; Barthel H; Sabri O; Müller U; Meissner WG; Kovacs GG; Höglinger GU
    Prog Neurobiol; 2019 Sep; 180():101644. PubMed ID: 31238088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new non-aggregative splicing isoform of human Tau is decreased in Alzheimer's disease.
    García-Escudero V; Ruiz-Gabarre D; Gargini R; Pérez M; García E; Cuadros R; Hernández IH; Cabrera JR; García-Escudero R; Lucas JJ; Hernández F; Ávila J
    Acta Neuropathol; 2021 Jul; 142(1):159-177. PubMed ID: 33934221
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Prion-Like Behavior of Assembled Tau in Transgenic Mice.
    Clavaguera F; Tolnay M; Goedert M
    Cold Spring Harb Perspect Med; 2017 Oct; 7(10):. PubMed ID: 27940600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.